Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Follistatin 344

FS-344, Activin-Binding Protein, FST344

Quick Stats
Studies 2
Trials 73
Completed NA INTERVENTIONAL NCT06721910

Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The goal of this proof-of-concept study is to learn if interleukin-6 changes the effect of glucagon in healthy volunteers. The main question it aims to answer is: Does IL-6 influence how effectively glucagon lowers the concentration of amino acids in blood? Researchers will compare the infusion of normal saline and a blocker of the receptor for interleukin-6 to see if blocking interluekin-6 changes how effectively glucagon lowers the concentration of amino acids in blood. Participants will be asked to * receive either an infusion of normal saline or the interleukin-6 receptor blocker * participate in a study visit three weeks later at which they will receive infusions of hormones and amino acids to mimic the concentrations of the hormones insulin and glucagon during fasting or fed conditions * labelled glucose, glycerol and amino acids will also be infused continuously to track the fate of these molecules * during the hormone infusions blood samples will be taken repeatedly

Interventions

Name: Tocilizumab
Type: DRUG
Description: Blockade of the interleukin-6 receptor
Name: Placebo
Type: OTHER
Description: Infusion of 100 ml normal saline

Primary Outcomes

Measure: Change in maximum glucagon-induced reduction in total plasma amino acid concentrations
TimeFrame: At visit 2 during high glucagon phase (80-120 minutes)
Description:

Trial Information

NCT ID

NCT06721910

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

University Hospital, Basel, Switzerland

Last Updated

December 15, 2025

Related Peptides